The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers by Joseph Edward Haigh, Karan Patel, Sam Rack, Pablo Jiménez-Labaig, Guy Betts, Kevin Joseph Harrington, Robert Metcalf

Subjects: Get full text

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy? by Wiebren Tjalma, Laure-Anne Teuwen, Sevilay Altintas, Konstantinos Papadimitriou

Subjects: Get full text

Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study by Junxiao Wang, Yushuai Yu, Qisheng Lin, Xin Wang

Subjects: “…Trastuzumab emtansine…”
Get full text

Development and Validation of the ELISA Method for Anti-trastuzumab Antibodies Determination in Human Serum by O. A. Eliseeva, M. A. Kolganova, I. E. Shokhin, S. P. Dementyev, A. M. Vlasov, A. A. Zamyatnin, N. S. Dubovik, A. Yu. Savchenko, N. V. Dozmorova, V. G. Luzhanin

Subjects: “…trastuzumab…”
Get full text

Validation of ELISA Test-system for Trastuzumab (Herceptin, Hertikad) quantitative determination in biological fluids by V. V. Pisarev, A. V. Ivanov

Subjects: “…trastuzumab…”
Get full text

Trastuzumab and cardiotoxicity by Petra Sertić, Petra Jakšić, Mihaela Trajbar, Ljubica Vazdar, Robert Šeparović, Ana Tečić-Vuger

Subjects: Get full text

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case) by A.   F. Nasretdinov, A.   V. Pushkarev, O.  N.  Lipatov, N.   I. Sultanbaeva, Sh.   I. Musin, K.   V. Menshikov, A.   A. Izmailov, V.   A. Pushkarev, M.   G. Galeev, R.   R. Muginov, R.   B. Valiakhmedov, D.   D. Sakaeva, A.   V. Sultanbaev

Subjects: Get full text

Cardiotoxicity in chemotherapeutic agents by Vitorino Modesto dos Santos, Lister Arruda Modesto dos Santos

Subjects: Get full text

A Double-blind Randomized Comparative Phase I Study to Assess Biosimilarity and Immunogenicity of "Trastuzumab" (LLC "Mabscale", Russia) and Herceptin® (F. Hoffmann-La Roche Ltd.,... by M. A. Kolganova, E. E. Beketov, V. V. Pisarev, A. V. Ivanov, S. V. Vasiliev, I. E. Shokhin

Subjects: “…trastuzumab…”
Get full text

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer by Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho

Subjects: “…Trastuzumab-Deruxtecan…”
Get full text

HER2-Positive Breast Cancer—Current Treatment Management and New Therapeutic Methods for Brain Metastasis by Hanna Miski, Kamila Krupa, Michał Piotr Budzik, Andrzej Deptała, Anna Badowska-Kozakiewicz

Subjects: Get full text

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan by Negar Pourjamal, Vadim Le Joncour, György Vereb, Cilla Honkamaki, Jorma Isola, Jeffrey V Leyton, Pirjo Laakkonen, Heikki Joensuu, Mark Barok

Subjects: Get full text

Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia by N. A. Avxentyev, Yu. V. Makarova, A. S. Makarov

Subjects: Get full text

Trastuzumab-Induced Organising Pneumonia in Breast Cancer Patient by Sapna Dixit, Jyoti Bajpai, Surya Kant, Ajay Kumar Verma, Puneet Prakash

Subjects: Get full text

Target therapy in treatment of HER2-positive breast cancer by A. S. Belokhvostova, I. A. Smirnova, A. A. Enileeva

Subjects: Get full text

Correlation between CTMP expression levels and resistance to trastuzumab in HER2 + metastatic breast cancer by Mania Makhoul, Maher Saifo, Fariz Ahmad, Jumana Saleh

Subjects: Get full text

Comprehensive management strategy of interstitial lung disease induced by trastuzumab deruxtecan by ZHANG Jian, HAN Qian, XU Fei, GAN Lu, CHEN Zhanhong, MA Li, WANG Hao, LIU Jieqiong, WU Xiaohong, CAI Li, ZHAO Bing, LÜ Zheng, LI Li, NI Sujie, HU Xichun

Subjects: “…|interstitial lung disease|trastuzumab deruxtecan|management…”
Get full text

Olası Trastuzumab Kullanımına Bağlı Gelişen Pyojenik Granülom by Hilmi Cevdet Altınyazar, Özlem Bilgiç

Subjects: “…trastuzumab…”
Get full text

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade by V. F. Semiglazov, N. B. Bekkeldieva, P. V. Krivorotko, A. V. Komyakhov, R. M. Paltuev, A. I. Tseluyko, L. P. Gigolaeva, T. T. Tabagua, E. K. Zhiltsova, V. S. Apollonova, G. A. Dashyan, A. G. Kudaybergenova, V. G. Ivanov, A. A. Bozhok, D. G. Ulrikh, A. O. Gorina, T. Yu. Semiglazova

Subjects: Get full text

Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report by Patricia Miranda Romero, Roberto Marín Gil

Subjects: Get full text